Crucell Ends PER.C6® Patent Infringement Case as Final Demands are Satisfied

Leiden, The Netherlands, 9 May, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that the patent infringement proceedings before the Düsseldorf District court against CEVEC Pharmaceuticals GmbH have finally been settled. As part of the court settlement, Crucell has withdrawn the one remaining claim in this procedure. The claim sought destruction of a N52E6 cell bank made prior to the grant of Crucell’s European PER.C6® patent that resides outside the jurisdiction of the Düsseldorf court, but is still under the control of CEVEC.

The withdrawal of the claim follows CEVEC’s commitment that it will not use, nor grant permission to use the cell bank in future in any way that infringes Crucell’s PER.C6® patent. The infringement of the N52E6 cells in Germany subsequent to the grant of Crucell’s PER.C6® patent had already been acknowledged by the Düsseldorf court on December 14, 2004, as reported by Crucell in a press release dated December 16, 2004.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes vaccines against hepatitis B and virosomal influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, elsewhere in Europe, and in Korea. The Company employs about 900 people. For more information, please visit www.crucell.com.

Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

Contact Information

Harry Suykerbuyk

Director Investor Relations & Corporate Communications

Crucell N.V.

Contact via E-mail